Hearing Loss, Cisplatin-Induced (CIHL)

External Ids:

OMIM® 57 613290

OMIM® : ⁵⁷ Cisplatin is a highly effective chemotherapeutic agent, but its use is restricted by the high incidence of irreversible ototoxicity associated with it. This ototoxicity causes serious permanent bilateral hearing loss in 10 to 25% of adults receiving the drug, and in up to 60% of children. The consequences of this ototoxicity are particularly serious in children, because even mild hearing loss can compromise language and cognitive development. Cisplatin ototoxicity frequently leads to dose reduction and premature termination of cisplatin treatment, which may affect overall survival rates (summary by Ross et al., 2009). (613290) (Updated 20-May-2021)

MalaCards based summary : Hearing Loss, Cisplatin-Induced, is also known as hearing loss, cisplatin-induced, susceptibility to. An important gene associated with Hearing Loss, Cisplatin-Induced is CIHL (Hearing Loss, Cisplatin-Induced, Susceptibility To). Affiliated tissues include eye.

Clinical features from OMIM®:

613290 (Updated 20-May-2021)

Search Clinical Trials , NIH Clinical Center for Hearing Loss, Cisplatin-Induced

Search GEO for disease gene expression data for Hearing Loss, Cisplatin-Induced.